DEEP DIVE

Sermorelin

What is sermorelin?

Sermorelin is a peptide made of 29 amino acids. It is a fragment of growth hormone releasing hormone, or GHRH. Researchers study how it signals the pituitary gland to release growth hormone.

Last updated: 2026-10-08

At a Glance

Full Name: Sermorelin acetate (GRF 1-29 NH₂)

Class: Growth hormone releasing hormone (GHRH) analog

Sequence: First 29 amino acids of GHRH(1-44)

Molecular Weight: 3,357.93 Da

CAS Number: 86168-78-7

Target: GHRH receptor (pituitary somatotrophs)

FDA History: Approved as Geref (1997), discontinued 2008 (business reasons)

Half-Life: ~10-20 minutes (preserves pulsatility)

Key Distinction: Stimulates natural GH production (not exogenous GH)

IN THIS ARTICLE

Why is Sermorelin studied?How does Sermorelin work in research models?What does the evidence show?Sermorelin vs. Other GH Secretagogues What are the limits of the safety evidence?What questions remain for future research?FAQ References

Why is Sermorelin studied?

Sermorelin is studied in the growth hormone signaling system. It acts at the GHRH receptor. This differs from directly supplying growth hormone.

The pituitary is a small gland involved in hormone release. GH means growth hormone. Researchers examine how GHRH signals affect GH release and its timing.

The historical medicine Geref forms part of the cited background. Its history does not establish the safety of current research inventory. It also does not prove an anti-aging effect.

How does Sermorelin work in research models?

GHRH is growth hormone releasing hormone. Sermorelin contains its first 29 amino acids. It is studied for signaling at receptors on pituitary cells.

Pulsatile release means hormone release in bursts rather than a constant level. Researchers measure this pattern and related cellular signals. These measurements do not establish a clinical benefit by themselves.

IGF-1 means insulin-like growth factor 1. Feedback involves signals that limit further hormone release. A feedback mechanism is not a guarantee against harm or hormone excess.

Sermorelin's Physiological Mechanism

GHRH Receptor Binding

Sermorelin acts at GHRH receptors on pituitary cells. These cells are involved in growth hormone release.

GH Gene Transcription

Transcription means using genetic instructions to make cellular products. Researchers examine signaling linked to growth hormone production.

Pulsatile GH Secretion

Pulsatile secretion means release in bursts. Studies measure the timing and amount of growth hormone release.

IGF-1 Production

IGF-1 is insulin-like growth factor 1. Researchers measure it as part of the growth hormone signaling system.

Negative Feedback Preservation

Feedback signals can limit further hormone release. They do not guarantee safety or prevent every adverse response.

Short Half-Life = Natural Pulsatility

Half-life describes how quickly a measured amount declines. Its effect on hormone patterns requires study-specific evidence.

What does the evidence show?

The cited literature includes historical clinical work and research in older adults. Study populations and the exact material must be checked. GHRH, growth hormone and sermorelin are not interchangeable names.

The inherited findings below include broader GH-axis sources. They should not all be read as direct trials of sermorelin. Multi-intervention work cannot isolate the effect of one compound.

FDA Clinical Trials (Geref)

Sermorelin was FDA-approved for diagnosis and treatment of pediatric growth hormone deficiency based on controlled clinical trials demonstrating significant increases in growth velocity, GH secretion, and IGF-1 levels with acceptable safety profiles. Approval covered both diagnostic (GH-release test) and therapeutic use.

FDA, Geref (sermorelin acetate) approval, 1997

Adult GH Deficiency

In adult GHD patients, sermorelin increased 24-hour integrated GH concentrations, restored pulsatile GH secretion patterns, and improved body composition (decreased fat mass, increased lean mass) without the supraphysiological GH peaks associated with hGH injection.

Vittone J, et al., J Clin Endocrinol Metab, 1997

Body Composition in Aging

In healthy older adults (ages 65-88), 6 months of sermorelin administration increased GH secretion, decreased abdominal visceral fat, improved skin thickness and elasticity, and did not adversely affect glucose metabolism or produce significant side effects.

Khorram O, et al., Clin Endocrinol, 1997

Sleep Quality Enhancement

Sermorelin administration before bedtime increased slow-wave (deep) sleep duration and improved sleep architecture. The largest natural GH pulse occurs during Stage 3/4 sleep, and sermorelin's stimulation of this pulse contributes to sleep quality improvement — one of the most consistently reported subjective benefits.

Multiple studies, reviewed in Sigalos & Pastuszak, 2018

Cardiac Function

In GH-deficient adults, sermorelin improved cardiac output, reduced systemic vascular resistance, and enhanced exercise capacity. These cardiovascular benefits mirror those of GH replacement but through physiological GH stimulation rather than exogenous administration.

Cittadini A, et al., J Clin Endocrinol Metab, 2002

Immune Function

GH-axis stimulation via sermorelin has been associated with improved thymic function, increased naive T-cell production, and enhanced immune surveillance — effects particularly relevant to the immunosenescence that accompanies aging.

Fahy GM, et al., Aging Cell, 2019 (TRIIM trial)

Sermorelin vs. Other GH Secretagogues

Sermorelin and CJC-1295 act at GHRH receptors. Ipamorelin and MK-677 act through a different receptor system. MK-677 is not a peptide.

Half-life means the time for a measured amount to fall by half under specified conditions. Differences in half-life do not establish a preferred treatment schedule. Combined receptor activity also does not prove a safe or effective blend.

Property	Sermorelin	Ipamorelin	CJC-1295 (DAC)	MK-677 (Oral)
Class	GHRH analog	GHRP (ghrelin mimetic)	GHRH analog (extended)	Ghrelin mimetic (oral)
Receptor Target	GHRH receptor	GHS receptor (ghrelin)	GHRH receptor	GHS receptor (ghrelin)
GH Release Pattern	Pulsatile (physiological)	Pulsatile (physiological)	Sustained elevation	Sustained elevation
Half-Life	~10-20 minutes	~2 hours	~8 days (with DAC)	~4-6 hours
Cortisol Effect	None	None	Minimal	None to minimal
Prolactin Effect	None	None	Minimal	Minimal
Hunger Stimulation	None	None	None	Significant (ghrelin pathway)
FDA History	Previously approved (Geref)	No FDA history	No FDA history	No FDA history
Safety Track Record	Longest, most established	Good (limited clinical data)	Limited clinical data	Oral convenience; less clinical data
Key Advantage	Best safety profile + FDA pedigree	Cleanest side effect profile	Once-weekly dosing convenience	Oral administration

What are the limits of the safety evidence?

Historical trials report local reactions, flushing and other observations. The tested population and preparation matter. Natural hormone feedback does not guarantee safety.

Short studies cannot exclude every long-term risk. Broad claims that a compound is the safest in its class require direct comparative evidence. These materials are for laboratory research, not personal hormone treatment.

Common: Injection site reactions (redness, swelling, pain), transient facial flushing

Uncommon: Headache, dizziness, drowsiness (typically mild and transient)

Not Observed: No significant cortisol elevation, no prolactin increase, no appetite stimulation, no glucose impairment

Long-Term Safety: No significant adverse effects reported in extended clinical use; FDA withdrawal was business-related, not safety-related

What questions remain for future research?

Aging research and growth hormone research sometimes overlap. That does not establish that sermorelin reverses aging. Changes in a biomarker are not proof of improved lifespan or health.

The TRIIM reference concerns a multi-intervention study. It cannot establish a sermorelin-specific effect. Future questions need studies that identify the actual compound and isolate its contribution.

Frequently Asked Questions

What is sermorelin?

Sermorelin is a peptide made of 29 amino acids. It is a fragment of growth hormone releasing hormone, or GHRH. Researchers study how it signals the pituitary gland to release growth hormone.

How does sermorelin differ from hGH injection?

Sermorelin signals through the GHRH receptor. Direct growth hormone administration supplies the downstream hormone. The distinction does not guarantee that one approach is safer in every setting.

Why was Geref (sermorelin) discontinued?

Geref was withdrawn from the market in 2008 by the manufacturer (EMD Serono) for business reasons — not due to safety concerns. The compound's safety record from FDA-supervised clinical trials remains clean and well-documented.

What are the benefits of sermorelin in aging?

Older-adult studies explore growth hormone signaling and related measurements. The exact compound and study design matter. These findings do not establish aging reversal.

Can sermorelin be combined with ipamorelin?

The compounds act through different receptors. This creates a research question, not proof of a safe or effective combination. Direct evidence for the exact materials is needed.

What are the side effects of sermorelin?

Historical studies report local reactions and flushing, among other observations. Frequency depends on the study conditions. Short trials cannot exclude every long-term risk.

Is sermorelin FDA-approved?

Sermorelin was FDA-approved as Geref from 1997 to 2008. It was voluntarily withdrawn by the manufacturer for commercial reasons. It is currently available for research purposes. Its former FDA approval gives it a clinical pedigree unmatched by any other GH secretagogue.

References

[1] Geref (sermorelin acetate for injection). FDA Prescribing Information. EMD Serono, 1997.
[2] Vittone J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96.
[3] Khorram O, et al. Activation of immune function by GHRH administered to normal men. J Clin Endocrinol Metab. 1997;82(11):3590-3596.
[4] Fahy GM, et al. Reversal of epigenetic aging and immunosenescent trends in humans (TRIIM). Aging Cell. 2019;18(6):e13028.
[5] Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53.
[6] Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308.
[7] Cittadini A, et al. Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction. J Clin Endocrinol Metab. 2002;87(6):3164-3170.